Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding

Veracyte (VCYT) Shares Issued (2016 - 2025)

Veracyte (VCYT) has disclosed Shares Issued for 14 consecutive years, with $3.5 million as the latest value for Q4 2025.

Quarterly Shares Issued rose 7.54% to $3.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.1 million through Dec 2025, down 29.57% year-over-year, with the annual reading at $14.1 million for FY2025, 29.57% down from the prior year.
Shares Issued hit $3.5 million in Q4 2025 for Veracyte, down from $5.8 million in the prior quarter.
In the past five years, Shares Issued ranged from a high of $593.8 million in Q1 2021 to a low of $340000.0 in Q2 2022.
Historically, Shares Issued has averaged $38.0 million across 5 years, with a median of $3.0 million in 2025.
Biggest five-year swings in Shares Issued: surged 28380.62% in 2021 and later crashed 99.4% in 2022.
Year by year, Shares Issued stood at $593.8 million in 2021, then crashed by 99.7% to $1.8 million in 2022, then decreased by 1.99% to $1.8 million in 2023, then surged by 84.2% to $3.3 million in 2024, then grew by 7.54% to $3.5 million in 2025.
Business Quant data shows Shares Issued for VCYT at $3.5 million in Q4 2025, $5.8 million in Q3 2025, and $1.8 million in Q2 2025.